轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02575 轩竹生物-B

未开盘 04-13 16:08:47

31.000

-1.360

-4.20%

最高32.760	最低30.520	成交量71.25万
今开31.320	昨收32.360	日振幅6.92%
总市值160.58亿	流通市值49.82亿	总股本5.18亿
成交额2,229万	换手率0.44%	流通股本1.61亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":31,"timestamp":1776067727196,"preClose":32.36,"halted":0,"volume":712500,"delay":0,"changeRate":-0.042027194066749055,"floatShares":160701996,"shares":518000000,"eps":-0.6086846824271943,"marketStatus":"未开盘","change":-1.36,"latestTime":"04-13 16:08:47","open":31.32,"high":32.76,"low":30.52,"amount":22291290,"amplitude":0.069221,"askPrice":31.04,"askSize":500,"bidPrice":31,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.6029423741024095,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776130200000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":32.36,"openAndCloseTimeList":[[1776043800000,1776052800000],[1776056400000,1776067200000]],"volumeRatio":0.42124847047363057,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575/wiki","defaultTab":"wiki","newsList":[{"id":"2626172948","title":"轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2626172948","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626172948?lang=zh_cn&edition=full","pubTime":"2026-04-12 18:04","pubTimestamp":1775988261,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)公布，近日公司接获中国证监会就其申请H股全流通发出的正式备案通知书,据此，公司已完成有关六名股东持有的合共357,245,794股未上市股份按一对一的基准转换为357,245,794股H股的中国证监会备案。该等357,245,794股H股将于完成有关转换及联交所授出上市批准后于联交所主板上市及买卖。通知自中国证监会批准之日(即 2026年3月26日)起12个月内有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)就申请建议实施H股全流通获中国证监会发出通知书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626215218","title":"港股异动 | 轩竹生物-B(02575)早盘涨超10% 与Boston Oncology就轩悦宁、轩菲宁订立许可及供货协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626215218","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626215218?lang=zh_cn&edition=full","pubTime":"2026-04-10 09:31","pubTimestamp":1775784710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超10%，截至发稿，涨9.96%，报34.46港元，成交额341.38万港元。消息面上，轩竹生物-B发布公告，于2026年4月9日，集团(许可人)与Boston Oncology CGT Holding Co. Limited就吡洛西利、地罗阿克订立许可及供货协议(本协议)。根据许可及供货协议，许可人将授予被许可人独占许可，允许其在授权区域开发、注册并商业化吡洛西利与地罗阿克。许可人将根据双方约定的产品供应价格向被许可人供货，以满足两款药品在授权区域内的商业开发活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426884.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","VXUS","BK1191","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124835429","title":"轩竹生物-B更新3月股份变动月报表，股本保持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1124835429","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124835429?lang=zh_cn&edition=full","pubTime":"2026-04-09 17:31","pubTimestamp":1775727079,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司（股票代码：02575，简称“轩竹生物-B”）于2026年4月9日披露2026年3月股份变动月报表。报告期为2026年3月1日至3月31日，公司股本结构及各类已发行股份数均与上月持平。\n公司H股数量维持在160,701,996股，未上市股份数量为357,245,794股，截至3月底合计已发行股份总数517,947,790股。报告期内，未见新增发行、购回、注销或库藏股变动，亦无涉及期权及股权激励计划的变化。\n公司同时确认继续遵守香港联交所相关上市规则及法律法规规定，符合对于公众持股量的要求。公告由联席公司秘书何成明签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166717383","title":"轩竹生物-B达成协议：集团将获超1亿美元付款及销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1166717383","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166717383?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:37","pubTimestamp":1775723845,"startTime":"0","endTime":"0","summary":"轩竹生物制药集团近日签署一项重要合作协议，根据协议条款，该集团将获得总额超过1亿美元的里程碑付款，并享有后续产品销售特许权使用费。此次合作标志着公司在创新药商业化领域取得突破性进展，资金注入将加速核心管线的临床开发与全球布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626022459","title":"轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2626022459","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626022459?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:36","pubTimestamp":1775723762,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，于2026年4月9日，集团(许可人)与Boston Oncology CGT Holding Co. Limited就吡洛西利、地罗阿克订立许可及供货协议(本协议)。根据许可及供货协议，许可人将授予被许可人独占许可，允许其在授权区域开发、注册并商业化吡洛西利与地罗阿克。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)与Boston Oncology 就吡洛西利、地罗阿克达成许可及供货协议","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120075030","title":"轩竹生物-B与波士顿肿瘤达成Bireociclib与Dirozalkib授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120075030","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120075030?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:34","pubTimestamp":1775723655,"startTime":"0","endTime":"0","summary":"2026年4月9日，轩竹生物-B（股票代码：02575）宣布与波士顿肿瘤（Boston Oncology）签署授权协议，就创新药物Bireociclib与Dirozalkib的开发及商业化达成战略合作。此举标志着公司在肿瘤治疗领域的全球布局迈出关键一步，有望通过资源整合加速两款候选药物的临床推进与市场拓展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102576666","title":"异动解读 | 轩竹生物-B盘中大涨12.96%，年度业绩亮眼及商业化进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1102576666","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102576666?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:53","pubTimestamp":1775094813,"startTime":"0","endTime":"0","summary":"轩竹生物-B(02575)今日盘中大涨12.96%，引起了市场的广泛关注。消息面上，公司近日发布了截至2025年12月31日止年度的业绩报告，显示其收入同比增长72.03%，达到5177.2万元；毛利同比大幅增加102.33%，至3336.9万元；同时，母公司拥有人应占亏损同比收窄55.88%，业绩表现显著改善。此外，公司在商业化布局方面也取得积极进展，其消化系统疾病药物安久卫®已搭建覆盖超90家分销商、辐射全国超2000家医疗机构的销售网络；肿瘤药物轩悦宁®及轩菲宁®的商业化推广也组建了超150人的专业化团队，有序推进产品在境内的商业化进程，这些因素共同增强了投资者对公司未来发展的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624526103","title":"港股异动 | 轩竹生物-B(02575)早盘涨超12% 25年度毛利同比增加102.33% 安久卫®商业化布局扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2624526103","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624526103?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:45","pubTimestamp":1775094334,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超12%，截至发稿，涨12.24%，报34港元，成交额650.58万港元。消息面上，近日，轩竹生物-B发布截至2025年12月31日止年度业绩，该集团取得收入5177.2万元，同比增加72.03%；毛利3336.9万元，同比增加102.33%；母公司拥有人应占亏损2.46亿元，同比收窄55.88%；每股亏损0.53元。报告期内，本集团采取灵活且有针对性的商业战略，以最大限度地发挥每款上市产品和目标市场的优势，并取得令人瞩目的成绩。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4585","VXUS","BK1191","BK4588","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315062","title":"轩竹生物-B(02575)发布年度业绩，收入5177.2万元 同比增加72.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623315062?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:03","pubTimestamp":1774864999,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布截至2025年12月31日止年度业绩，该集团取得收入5177.2万元，同比增加72.03%;毛利3336.9万元，同比增加102.33%;母公司拥有人应占亏损2.46亿元，同比收窄55.88%;每股亏损0.53元。报告期内，本集团采取灵活且有针对性的商业战略，以最大限度地发挥每款上市产品和目标市场的优势，并取得令人瞩目的成绩。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"轩竹生物-B(02575)发布年度业绩，收入5177.2万元 同比增加72.03%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622881272","title":"港股异动 | 轩竹生物-B(02575)早盘涨超18% 吡洛西利III期BRIGHT-2临床研究结果于国际医学顶刊发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2622881272","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622881272?lang=zh_cn&edition=full","pubTime":"2026-03-26 09:47","pubTimestamp":1774489669,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，轩竹生物-B早盘涨超18%，截至发稿，涨11.85%，报40.58港元，成交额1886.4万港元。消息面上，3月24日，轩竹生物-B发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。公司曾于2025年4月在《Nature Communications》期刊上公布BRIGHT-2研究的中期分析结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02575","BK0114","BK0236","BK0181","BK4585","VXUS","000516","BK0188","BK0096","BK4134","III","BK0046","BK0146","BK1191","BK0077","BK0042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621206968","title":"轩竹生物-B(02575)：吡洛西利联合氟维司群治疗HR+/HER2-晚期乳腺癌III期临床研究最终分析结果于国际顶尖期刊《JAMA Oncology》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2621206968","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621206968?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:12","pubTimestamp":1774350738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，公司自主研发的新型CDK2/4/6抑制剂吡洛西利的III期BRIGHT-2临床研究最终分析结果，已于近日在国际顶尖医学期刊《美国医学会杂志·肿瘤学》正式在线全文发表。BRIGHT-2研究最终分析结果显示，吡洛西利联合氟维司群为患者带来了具有临床意义且持久稳健的获益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02575","BK1191","BK4203","BK4225","HR","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621603174","title":"轩竹生物-B(02575)涨逾8% 安久卫治疗反流性食管炎III期试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621603174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621603174?lang=zh_cn&edition=full","pubTime":"2026-03-24 10:10","pubTimestamp":1774318245,"startTime":"0","endTime":"0","summary":"消息面上，四环医药发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","00460","BK4134","02575","BK1600","III","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621714992","title":"轩竹生物-B(02575)：安奈拉唑钠肠溶片(安久卫®)治疗反流性食管炎中国III期临床试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621714992","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621714992?lang=zh_cn&edition=full","pubTime":"2026-03-22 18:33","pubTimestamp":1774175605,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，公司自主研发的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已于近日顺利完成全部500名受试者入组。该项III期临床试验是一项多中心、随机、双盲双模拟、阳性药物平行对照的关键性研究，旨在评估安奈拉唑钠肠溶片治疗中国成年反流性食管炎受试者的有效性和安全性。安全性指标主要为不良事件的发生类型、发生率、严重程度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417067.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","02575","BK4134","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130891814","title":"轩竹生物-B一度飙升60%！吡洛西利片一线适应症近日获批，入通后资金抢跑布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1130891814","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130891814?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:24","pubTimestamp":1773887083,"startTime":"0","endTime":"0","summary":"3月19日，轩竹生物-B一度飙升60%！轩竹股价在3月9日大幅收涨8.30%，当日股票成交额达到4838.75万港元，较年内日均成交额2244万港元，大幅上涨约116%，入通次日公司股票单日成交额继续上涨至6195.59万港元，显示出港股通资金对轩竹生物的“抢跑布局”。实际上，轩竹生物在二级市场交投活跃度快速回升并获资金抢跑布局，主要得益于市场投资者对公司明确的“创新-商业化”投资逻辑的认可。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f3c7b18acd8da97ebbf23072ff5b0a2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620991292","title":"轩竹生物-B(02575)涨44.57% 日前获纳入港股通 吡洛西利片一线适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620991292","media":"金吾财讯","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620991292?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:41","pubTimestamp":1773884484,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B(02575)股价大幅拉升，截至发稿，涨44.57%，报62.05港元，成交额2133万港元。消息面上，日前，沪深交易所发布公告，调整港股通标的。公告显示，港股通标的名单发生调整，并自3月9日起生效。其中，轩竹生物被调入港股通标的名单。此外，轩竹生物自研1类创新药吡洛西利片获国家药监局批准新增适应症，可联合芳香化酶抑制剂（AI），用于HR+/HER2-晚期乳腺癌患者初始内分泌治疗。这一进展标志着吡洛西利从后线治疗正式挺进一线治疗领域，为我国HR+/HER2-晚期乳腺癌患者提供了疗效卓越、安全便捷的全新治疗选择。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f3c7b18acd8da97ebbf23072ff5b0a2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976798","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK4585","02575","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620137274","title":"入通靴子落地加速创新价值兑现，轩竹生物-B(02575)迎关键配置窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620137274?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:26","pubTimestamp":1773707180,"startTime":"0","endTime":"0","summary":"近日，事关创新药的政策利好不断。这对于在二级市场顺利“入通”、核心创新品种一线适应症获批的轩竹生物-B而言，无疑是极大利好。“入通”靴子落地，资金抢跑布局拉长时间线来看，2025年全年，港股通日均成交额为1211亿港元，占港股整体日均成交额的比重达到26.2%。轩悦宁强势挺进乳腺癌一线治疗，引发了业界和市场广泛关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468322","title":"轩竹生物-B(02575.HK)拟3月30日举行董事会会议审批全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468322","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619468322?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:17","pubTimestamp":1773663424,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨轩竹生物-B(02575.HK)宣布，董事会会议将于2026年3月30日(星期一)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度之全年业绩及其刊发，并考虑建议派发末期股息(如有)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618905006","title":"轩竹生物-B盘中异动 早盘快速下跌5.35%报49.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618905006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618905006?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:31","pubTimestamp":1773282702,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘10时31分，轩竹生物-B股票出现异动，股价快速下挫5.35%。截至发稿，该股报49.500港元/股，成交量18.7万股，换手率0.12%，振幅5.93%。资金方面，该股资金流入540.012万港元，流出361.313万港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。轩竹生物-B股票所在的生物技术行业中，整体跌幅为1.16%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618643080","title":"港股轩竹生物-B尾盘涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618643080","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618643080?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:52","pubTimestamp":1773042721,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月9日，轩竹生物-B(02575.HK)尾盘涨超10%，截至发稿涨10.3%，报55.15港元，成交额4197.63万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666060581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666060581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK1191","VXUS","02575","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618369053","title":"港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618369053","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618369053?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:03","pubTimestamp":1773018197,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：阿得贝利单抗注射液获得药物临床试验批准通知书安井食品(02648)拟向河南子公司增资1.2亿元轩竹生物-B(02575)获纳入港股通股票名单派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单滨海投资(02886)获提供不超过4500万美元及1.73亿","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359201885.HKD","LU0251143458.SGD","VT","IE0032834883.USD","BK1191","LU0259732245.USD","LU0106959298.USD","LU0348788117.USD","LU1769817096.USD","LU1769817179.HKD","IE00B0169L03.USD","02652","LU0651946864.USD","IE0008368742.USD","LU1048588211.SGD","LU0594300419.USD","BK1521","LU0163747925.USD","LU0315179316.USD","LU0737861699.HKD","LU1224709979.USD","LU0287142896.SGD","IE00B97KM107.HKD","IE00B031HY20.USD","02575","LU1115378108.SGD","SG9999002828.SGD","HK0000306701.USD","LU0370786039.SGD","IE00B29SXG58.USD","LU2125910500.SGD","LU0128522157.USD","LU0588546209.SGD","BK1553","LU0650527681.SGD","IE0009570106.USD","IE00B031J352.USD","BK1237","HK0000320264.USD","LU0307460666.USD","LU0359201612.USD","02319","LU2045819591.USD","LU0672654166.SGD","LU0823426308.USD","VXUS","BK1597","LU0029875118.USD","LU0211977185.USD","LU0072462343.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0019},{"period":"1month","weight":-0.38},{"period":"3month","weight":-0.5338},{"period":"6month","weight":0.1787},{"period":"ytd","weight":-0.5603}],"compareEarnings":[{"period":"1week","weight":0.0217},{"period":"1month","weight":0.0077},{"period":"3month","weight":-0.0442},{"period":"6month","weight":-0.0096},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.0012}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}